Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 5405847, 8 pages
http://dx.doi.org/10.1155/2016/5405847
Research Article

The Oxidative and Inflammatory State in Patients with Acute Renal Graft Dysfunction Treated with Tacrolimus

1Institute of Experimental and Clinical Therapeutics, Department of Physiology, University Health Sciences Centre, University of Guadalajara, Guadalajara, JAL, Mexico
2Department of Nephrology and Transplants, Specialties Hospital, National Occidental Medical Centre, The Mexican Social Security Institute, Guadalajara, JAL, Mexico
3Kidney Diseases Medical Research Unit, Specialties Hospital, National Occidental Medical Centre, The Mexican Social Security Institute, Guadalajara, JAL, Mexico

Received 4 August 2016; Revised 21 September 2016; Accepted 28 September 2016

Academic Editor: Sharad S. Singhal

Copyright © 2016 Sandra Carrillo-Ibarra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. L. White, S. J. Chadban, S. Jan, J. R. Chapman, and A. Cass, “How can we achieve global equity in provision of renal replacement therapy?” Bulletin of the World Health Organization, vol. 86, no. 3, pp. 229–237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. Guía de Práctica Clínica, Prevención, Diagnóstico y Tratamiento de la Enfermedad Renal Crónica Temprana, Secretaría Nacional de Salud, Mexico City, Mexico, 2009.
  3. A. Figueroa-Lara, M. A. Gonzalez-Block, and J. Alarcon-Irigoyen, “Medical expenditure for chronic diseases in Mexico: the case of selected diagnoses treated by the largest care providers,” PLoS ONE, vol. 11, no. 1, Article ID e0145177, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. Guidelines Network, Diagnosis and Management of Chronic Kidney Disease, Scottish Intercollegiate, SIGN, 2008.
  5. United Stated Renal Data System (USRDS), Consultada en Junio de, 2016, http://www.usrds.org/
  6. K. E. Lamb, S. Lodhi, and H.-U. Meier-Kriesche, “Long-term renal allograft survival in the United States: a critical reappraisal,” American Journal of Transplantation, vol. 11, no. 3, pp. 450–462, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. E. Staatz and S. E. Tett, “Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation,” Clinical Pharmacokinetics, vol. 43, no. 10, pp. 623–653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Sola, M. Gonzalez-Molina, M. Cabello et al., “Long-term improvement of deceased donor renal allograft survival since 1996: A Single Transplant Center Study,” Transplantation, vol. 89, no. 6, pp. 714–720, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Moreso, A. Alonso, M. A. Gentil et al., “Improvement in late renal allograft survival between 1990 and 2002 in Spain: results from a multicentre case-control study,” Transplant International, vol. 23, no. 9, pp. 907–913, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. Cueto-Manzano, E. Rojas, G. Rosales et al., “Risk factors for long-term graft loss in kidney transplantation: experience of a Mexican single-center,” Revista de Investigación Clínica, vol. 54, pp. 492–496, 2002. View at Google Scholar
  11. F. J. Monteón, B. Gómez, C. Valdespino et al., “The kidney transplant experience at Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara México,” Clinical Transplants, pp. 165–174, 2003. View at Google Scholar · View at Scopus
  12. C. Legendre, G. Canaud, and F. Martinez, “Factors influencing long-term outcome after kidney transplantation,” Transplant International, vol. 27, no. 1, pp. 19–27, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. Kidney Disease, “Improving Global Outcomes (KDIGO) Transplant Work Group KDIGO clinical practice guideline for the care of kidney transplant recipients,” American Journal of Transplantation, vol. 9, no. 3, pp. S1–S155, 2009. View at Google Scholar
  14. S. Cottone, A. Palermo, F. Vaccaro et al., “In renal transplanted patients inflammation and oxidative stress are interrelated,” Transplantation Proceedings, vol. 38, no. 4, pp. 1026–1030, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Juskowa, L. Paczek, T. Laskowska-Klita, Z. Rancewicz, J. Gajewska, and U. Jedynak-Ołdakowska, “Selected parameters of antioxidant capacity in renal allograft recipients,” Polskie Archiwum Medycyny Wewnetrznej, vol. 105, no. 1, pp. 19–27, 2001. View at Google Scholar · View at Scopus
  16. M. Salvadori, G. Rosso, and E. Bertoni, “Update on ischemia-reperfusion injury in kidney transplantation: pathogenesis and treatment,” World Journal of Transplantation, vol. 5, no. 2, pp. 52–67, 2015. View at Google Scholar
  17. E. M. Simmons, A. Langone, M. T. Sezer et al., “Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients,” Transplantation, vol. 79, no. 8, pp. 914–919, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Gago, L. D. Cornell, W. K. Kremers, M. D. Stegall, and F. G. Cosio, “Kidney allograft inflammation and fibrosis, causes and consequences,” American Journal of Transplantation, vol. 12, no. 5, pp. 1199–1207, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Solez, R. B. Colvin, L. C. Racusen et al., “Banff 07 classification of renal allograft pathology: updates and future directions,” American Journal of Transplantation, vol. 8, no. 4, pp. 753–760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. C. Farney, J. Rogers, G. Orlando et al., “Evolving experience using kidneys from deceased donors with terminal acute kidney injury,” Journal of the American College of Surgeons, vol. 216, no. 4, pp. 645–656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. A. J. Matas, J. M. Smith, and M. A. Skeans, “OPTN/SRTR 2011 annual data report: kidney,” American Journal of Transplantation, vol. 23, supplement 1, pp. 11–46, 2013. View at Publisher · View at Google Scholar
  22. J. A. Akoh and U. M. Thiyagarajan, “Renal Transplantation from Elderly Living Donors,” Journal of Transplantation, vol. 2013, Article ID 475964, 9 pages, 2013. View at Publisher · View at Google Scholar
  23. E. Solis-Vargas, L. A. Evangelista-Carrillo, A. Puentes-Camacho et al., “Epidemiological characteristics of the largest kidney transplant program in Mexico: western national medical center, Mexican institute of social security,” Transplantation Proceedings, vol. 48, no. 6, pp. 1999–2005, 2016. View at Publisher · View at Google Scholar
  24. A. Ibis, A. Altunoglu, A. Akgül et al., “Early onset proteinuria after renal transplantation: a marker for allograft dysfunction,” Transplantation Proceedings, vol. 39, no. 4, pp. 938–940, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Lee, T. Kim, S. Kang et al., “Association interleukin-4 and interleukin-4 receptor gene polymorphism and acute rejection and graft dysfunction after kidney transplantation,” Transplantation Proceedings, vol. 48, no. 3, pp. 813–819, 2016. View at Publisher · View at Google Scholar
  26. M. W. Taal and B. M. Brenner, “Predicting initiation and progression of chronic kidney disease: developing renal risk scores,” Kidney International, vol. 70, no. 10, pp. 1694–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Pascual, R. Marcén, and J. Ortuño, “Renal function: defining long-term success,” Nephrology Dialysis Transplantation, vol. 19, no. 6, pp. vi3–vi7, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. I. Lorenzen, A. Trad, and J. Grötzinger, “Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain,” Biochemical and Biophysical Research Communications, vol. 415, no. 2, pp. 330–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Baud and R. Ardaillou, “Tumor necrosis factor in renal injury,” Mineral and Electrolyte Metabolism, vol. 21, no. 4-5, pp. 336–341, 1995. View at Google Scholar · View at Scopus
  30. G. K. Sonkar, S. Singh, S. K. Sonkar, U. Singh, and R. G. Singh, “Evaluation of serum interleukin 6 and tumour necrosis factor alpha levels, and their association with various non-immunological parameters in renal transplant recipients,” Singapore Medical Journal, vol. 54, no. 9, pp. 511–515, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Boratyńska, M. Klinger, P. Szyber, D. Patrzalek, and K. Polak, “Interleukin-6 in chronic renal allograft rejection: influence of nonimmunologic risk factors,” Transplantation Proceedings, vol. 33, no. 1-2, pp. 1215–1217, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Akbari, D. Fergusson, M. B. Kokolo et al., “Spot urine protein measurements in kidney transplantation: a systematic review of diagnostic accuracy,” Nephrology Dialysis Transplantation, vol. 29, no. 4, pp. 919–926, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Benedetti, M. Comporti, and H. Esterbauer, “Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids,” Biochimica et Biophysica Acta, vol. 620, no. 2, pp. 281–296, 1980. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Goldring, A. F. Casini, E. Maellaro, B. Del Bello, and M. Comporti, “Determination of 4-hydroxynonenal by high-performance liquid chromatography with electrochemical detection,” Lipids, vol. 28, no. 2, pp. 141–145, 1993. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Comporti, B. Arezzini, C. Signorini, D. Vecchio, and C. Gardi, “Oxidative stress, isoprostanes and hepatic fibrosis,” Histology and Histopathology, vol. 24, no. 7, pp. 893–900, 2009. View at Google Scholar · View at Scopus
  36. D. Stojanovic, T. Cvetkovic, M. Stojanovic, V. Bojanic, N. Stefanovic, and I. Stojanovic, “The assessment of renalase: searching for the best predictor of early renal dysfunction by multivariate modeling in stable renal transplant recipients,” Annals of Transplantation, vol. 20, pp. 186–192, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. N. A. Simonian and J. T. Coyle, “Oxidative stress in neurodegenerative diseases,” Annual Review of Pharmacology and Toxicology, vol. 36, pp. 83–106, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Racasan, B. Braam, H. A. Koomans, and J. A. Joles, “Programming blood pressure in adult SHR by shifting perinatal balance of NO and reactive oxygen species toward NO: the inverted Barker phenomenon,” American Journal of Physiology—Renal Physiology, vol. 288, no. 4, pp. F626–F636, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Parra, G. de Arriba, J. R. Conejo et al., “Cyclosporine increases local glomerular synthesis of reactive oxygen species in rats: effect of vitamin E on cyclosporine nephrotoxicity,” Transplantation, vol. 66, no. 10, pp. 1325–1329, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Kidokoro, M. Satoh, H. Nagasu et al., “Tacrolimus induces glomerular injury via endothelial dysfunction caused by reactive oxygen species and inflammatory change,” Kidney and Blood Pressure Research, vol. 35, no. 6, pp. 549–557, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Kdzierska, M. Domaski, K. Sporniak-Tutak, B. Dogowska, and K. Ciechanowski, “Oxidative stress and renal interstitial fibrosis in patients after renal transplantation: current state of knowledge,” Transplantation Proceedings, vol. 43, no. 10, pp. 3577–3583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Naesens, D. R. J. Kuypers, and M. Sarwal, “Calcineurin inhibitor nephrotoxicity,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 2, pp. 481–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. A. J. Olyaei, A. M. de Mattos, and W. M. Bennett, “Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies,” Current Opinion in Critical Care, vol. 7, no. 6, pp. 384–389, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Djamali, “Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts,” American Journal of Physiology—Renal Physiology, vol. 293, no. 2, pp. F445–F455, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. U. Gresser and B. S. Gathof, “Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke-comparison of the clinical benefit of statins on the basis of randomised controlled endpoint studies,” European Journal of Medical Research, vol. 9, no. 1, pp. 1–17, 2004. View at Google Scholar · View at Scopus
  46. D. Williams and J. Feely, “Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors,” Clinical Pharmacokinetics, vol. 41, no. 5, pp. 343–370, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. P. F. Katsakiori, E. P. Papapetrou, D. S. Goumenos, G. C. Nikiforidis, and C. S. Flordellis, “Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: an interaction study in CYP3A5 non-expressors, renal transplant recipients,” Indian Journal of Pharmacology, vol. 43, no. 4, pp. 385–388, 2011. View at Publisher · View at Google Scholar · View at Scopus